ATLAS fair value
ATLAS has no fair value for this stock today.
Clearmind Medicine stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
Prices as of Oct 27, 2026 · USD
ATLAS has no fair value for this stock today.
39%
that it ends higher than today in 21 sessions
ATLAS's own quantitative analysis, all in one place.
Plans from €3.99 a month.
ATLAS's model gives Clearmind Medicine a 39% chance of finishing higher a month from now (21 trading sessions) than today: somewhat worse than a coin flip.
In half of the simulated outcomes the price ends between $3.85 and $7.15; in 9 out of 10, between $2.22 and $12.40. Estimated annual volatility is 200%.
ATLAS does not publish a fair value for CMND right now, but it does show its odds of rising: somewhat worse than a coin flip.
Its beta is -1.14: it tends to move less than the market.
Clearmind Medicine Inc. Common Shares represents equity in Clearmind Medicine Inc., a clinical-stage biotechnology company focused on developing novel psychedelic-derived therapeutics and neuroplastogen-based compounds for underserved health conditions.
Want to see everything about Clearmind Medicine?
Get started →Plans from €3.99 a month.
Other companies in the same line of business:
Clearmind Medicine Inc. Common Shares represents equity in Clearmind Medicine Inc., a clinical-stage biotechnology company focused on developing novel psychedelic-derived therapeutics and neuroplastogen-based compounds for underserved health conditions.
39%: somewhat worse than a coin flip. In half of the simulated outcomes, CMND ends the month between $3.85 and $7.15.
Clearmind Medicine's market capitalization is $2.4M. We do not show a P/E because it has no positive earnings to base one on.
ATLAS estimates annual volatility at 200%. In a typical month, half of the outcomes end between $3.85 and $7.15.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer
ATLAS Signals
The week in the market, three stocks on ATLAS’s radar and what comes next. Get it every Monday.
By subscribing you agree to receive ATLAS Signals by email every Monday. You can unsubscribe with one click at any time. Privacy